Skip to main content

Table 5 Pharmacokinetic parameters after oral administration of vorinostat suspension (pure drug) and optimized vorinostat-loaded SMEDDS (F7)

From: Improved oral bioavailability of poorly water-soluble vorinostat by self-microemulsifying drug delivery system

Parameters (units)

Group I (SMEDDS 10 mg/kg)

Group II (control)

API suspension 10 mg/kg)

Cmax (ng/mL)

24.62 ± 0.28*

15.50 ± 0.29

Tmax (h)

2.17 ± 0.02*

1.23 ± 0.09

AUC(0−∞) (ng/mL h)

1325.33 ± 16.28*

365.00 ± 12.76

t1/2 (h)

7.66 ± 0.18*

15.50 ± 0.28

MRT(0−∞) (h)

11.88 ± 0.08*

22.69 ± 0.36

F# (%)

363.10

–

  1. Values are expressed as mean ± SEM of 6 animals. Symbol represents the statistical significance performed by ANOVA, followed by Tukey–Kramer’s multiple comparison tests
  2. *p < 0.001 indicates the comparison of group I (SMEDDS) with group II (API suspension) treated animals. Maximum plasma concentration (Cmax). Time of maximum concentration (Tmax), area under curve extrapolated to infinity (AUC(0−∞)), elimination half-life (t1/2), mean residence time when the drug concentration profile is extrapolated to infinity (MRT(0−∞)), relative bioavailability (F#), active pharmaceutical ingredient-Vorinostat (API-Vorinostat)